Equities analysts forecast that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will post earnings of $4.50 per share for the current quarter, according to Zacks Investment Research. Eight analysts have issued estimates for Regeneron Pharmaceuticals’ earnings. The highest EPS estimate is $6.59 and the lowest is $3.54. Regeneron Pharmaceuticals reported earnings of $2.92 per share during the same quarter last year, which would suggest a positive year over year growth rate of 54.1%. The firm is expected to issue its next earnings report on Thursday, May 3rd.
On average, analysts expect that Regeneron Pharmaceuticals will report full-year earnings of $18.65 per share for the current financial year, with EPS estimates ranging from $15.49 to $24.15. For the next fiscal year, analysts forecast that the business will report earnings of $21.56 per share, with EPS estimates ranging from $17.67 to $25.34. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $4.18 by $1.05. Regeneron Pharmaceuticals had a return on equity of 28.48% and a net margin of 20.41%. The company had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.50 billion. During the same period in the prior year, the firm earned $3.04 earnings per share. The firm’s revenue for the quarter was up 28.9% on a year-over-year basis.
A number of research firms have recently commented on REGN. BTIG Research reissued a “buy” rating and issued a $520.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, November 22nd. Canaccord Genuity cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating and cut their target price for the stock from $522.00 to $356.00 in a research note on Wednesday. BMO Capital Markets set a $444.00 target price on Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research note on Monday, November 27th. Citigroup cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the stock from $480.00 to $380.00 in a research note on Friday, December 1st. Finally, Cowen reissued a “hold” rating and issued a $450.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, February 7th. Three investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $450.65.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of the stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $325.60, for a total value of $325,600.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 10.80% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of the business. Xact Kapitalforvaltning AB lifted its holdings in Regeneron Pharmaceuticals by 23.6% in the fourth quarter. Xact Kapitalforvaltning AB now owns 17,772 shares of the biopharmaceutical company’s stock valued at $6,682,000 after acquiring an additional 3,397 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its holdings in Regeneron Pharmaceuticals by 16.1% in the fourth quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 65,862 shares of the biopharmaceutical company’s stock valued at $24,761,000 after acquiring an additional 9,157 shares during the period. Pin Oak Investment Advisors Inc. bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $152,000. Compagnie Lombard Odier SCmA bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $561,000. Finally, Slow Capital Inc. bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $555,000. 64.67% of the stock is currently owned by institutional investors.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded down $9.11 during midday trading on Friday, hitting $323.04. The stock had a trading volume of 843,900 shares, compared to its average volume of 1,079,808. Regeneron Pharmaceuticals has a 52-week low of $313.53 and a 52-week high of $543.55. The stock has a market capitalization of $34,200.00, a PE ratio of 24.16, a P/E/G ratio of 1.04 and a beta of 1.47. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.18 and a current ratio of 3.82.
ILLEGAL ACTIVITY NOTICE: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/02/21/4-50-eps-expected-for-regeneron-pharmaceuticals-inc-regn-this-quarter.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.